Calling all Clinical Phase I Outsourcing Professionals!

Posted:
4
February 2007

Do You Outsource Phase I Clinical Trials?Outsourcing remains a critical aspect of clinical development. All major drug development projects rely on one or more partners to aid the drug development process. The 9th Annual Phase I Clinical Trials conference on 19-20 February at Olympia Conference Centre, London will highlight the following:

  • A timely update on the guidance for first man studies � the revision of EMEA guidelines
  • What are the challenges and priorities over the next five years for the MHRA
  • How to manage potentially 'high risk' complex molecules. Tegenero: a case study
  • The challenges of conducting phase I studies in patients

Get the answers you need to all your outsourcing questions and meet the team from Richmond Pharmacology, the Early Phase CRO that can help you achieve your goals.Wednesday 20 February 2008 at 2pm, Dr. Jörg Täubel MFPM, MD, Managing Director, Richmond Pharmacology, invites you to discuss "Why carry out Phase 1 Trials in the UK, focussing primarily on the regulatory implications of conducting Phase 1 studies in the UK".We look forward to meeting you at the Congress. Visit the Richmond Pharmacology team at Stand No 3 to discuss your Early Phase outsourcing requirements.Exhibitor DiscountAs exhibitors we are delighted to offer you a discount of 25% off the first person and 15% off each additional person after that if you would like to attend the conference. Please call Angela Davie, Business Development Manager, on 020 8664 5200 or book direct quoting our VIP CODE - TT30 and booking code TT30Spex.

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more